- American indices open in the green on Friday
- US100 on new highs
- USD Index falls 0.25%, bond yields are up
- Broadcom soars 20% and breakes over $1 trillion market cap
The last session of the week brings another wave of growth in technology stocks, particularly in the semiconductor and AI sectors. The star of today’s session is Broadcom, which gained 22% at the opening, breaking over the $1 trillion market cap mark.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app
Investor enthusiasm is once again fueled by groundbreaking products from companies in the tech sector. Earlier this week, companies linked to quantum technology gained significant attention following Alphabet's announcement of its advanced Willow chip. Today, investors’ focus has reversed back to AI, mainly due to Broadcom (AVGO.US). The company released very promising forecasts for the coming years and highlighted strong interest in its customized AI model products.
US100 (D1)
The Nasdaq 100 index, represented by the US100 contract, adds another 1.00% at the opening of the cash session, reaching a new high of 21,850 points. The next major hurdle for the bulls is likely the zone just below 22,000 points.
Source: xStation5
Corporate news:
- Broadcom’s (AVGO.US) shares rally on AI demand forecast (+22.15%), as reported by the company after its earnings call conference. The company expects 65% sales growth for their AI products in Q1 2025 and estimates that the market for the AI components will have grown to $90 bn by 2027. Optimistic sales outlook helps Broadcom’s stock to recover from moderate losses driven by the slight net revenue miss in Q4 2024 ($14.05 bn vs $14.08 bn expected).
- EVgo (EGO.US) trades 1.3% lower despite 12% premarket rally after the company closed a $1.25 bn guaranteed by the US Department of Energy to finance new public electric vehicle charging station
- Upstart (UPST.US) shares are up 8.9% after Needham upgraded its recommendation from ‘hold’ to ‘buy’, with price target $100 (currently: $83.93). The analysts argue that the Upstart’s balance sheet has significantly improved and expect even better funding environments in months to come.
- Vir Biotechnology (VIR.US) wins the FDA’s Breakthrough Therapy and European Medicines Agency’s Priority Medicine designations. The status received opens the door to the phase III clinical trial for the drugmaker’s treatment for chronic hepatitis delta (CHD). The registration for the trial is planned for the first half of 2025. Vir’s shares, though up 2% during premarket trading, are currently down 1%.
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
